Anemia of chronic kidney disease is more prevalent when GFR is under 60ml per minute as a consequence of loss of erythropoietin synthesis by the kidney. Target goals for treatment are hemoglobin levels of 12g per dL for males and 11g per dL for females. One randomized controlled trial in patients with chronic kidney disease without dialysis comparing erythropoietin treatment vs. placebo reported significant improvement in energy levels and work capacity in the treatment group. Iron supplementation is necessary for effective erythropoiesis. When there is inadequate response to rHu-EPO, folate and vitamin B12, status should also be evaluated. There are limited long-term studies of the benefits of rHu-EPO in chronic kidney disease (non-dialysis).